Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Multiple myeloma" and "Society guideline links: Immunoglobulin light chain (AL) amyloidosis" and "Society guideline links: Waldenström macroglobulinemia".)
●IMWG: Consensus perspectives risk factors for progression and guidelines for monitoring and management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma (2010)
●Choosing Wisely Canada: Don't request a serum protein electrophoresis in asymptomatic patients in the absence of otherwise unexplained hypercalcemia, renal insufficiency, anemia or lytic bone lesions (updated 2020)
●UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) (2009)
●[In Japanese] Japanese Society of Hematology (JSH): Hematopoietic tumor clinical practice guidelines, 2nd edition (2018, revised 2020)